Second opinion 6 min
Progression on treatment: what it means and what second-line therapy is
What it means when a scan shows growth during treatment, how progression is confirmed, what second-line therapy is and what to ask your doctor.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 23 October 2026
Progression means the tumour has grown or new lesions have appeared on CT, MRI or PET-CT during current treatment. The word is frightening, but it usually points to a practical question: what to change in the plan.
How progression is confirmed
- Scans are compared using the same method, ideally at the same centre, because different protocols change measured sizes.
- Immunotherapy is taken into account. It can cause pseudoprogression: lesions look larger for a while because of inflammation and then shrink. So the decision is sometimes confirmed with a repeat scan.
- Symptoms, blood tests and tumour markers are reviewed, but treatment is not changed on a marker alone.
What second-line therapy is
First line is the regimen you started with. If the disease grew on it, you move to a second line: different drugs or a different combination. The choice depends on the tumour type, previous treatment, molecular findings and your condition. A repeat biopsy, an NGS panel and clinical trials are usually discussed in parallel.
What not to do
- Do not stop or change treatment on your own before the doctor decides: a pause without a plan is often worse than a deliberate change of regimen.
- Do not rely on tumour markers alone: they hint, but do not replace scans.
- Do not postpone a repeat CT or MRI if the doctor has ordered it.
- Gather documents in advance: scan discs, pathology and molecular test results, and summaries with the dates of courses and drugs. With these any consultant can assess the situation faster.
Why a tumour stops responding
A tumour is not uniform: it contains cells with different sensitivity to drugs. Treatment removes sensitive cells while resistant ones remain and eventually start to grow. This is the biology of the disease, not the patient’s or doctor’s mistake.
Sometimes new mutations appear in the tumour and make the drug useless. That is why repeat molecular testing is often discussed at progression: it shows what has changed since the first biopsy.
Options after progression
- Next line of systemic therapy: other chemotherapy, a targeted drug or immunotherapy if not yet used.
- Local treatment. If one or two lesions have grown, radiotherapy, radiofrequency ablation or surgery are possible while systemic treatment continues.
- Clinical trial. For some patients this is the only route to new drugs; selection criteria are strict and are checked in advance.
- Supportive care. Pain relief, nutrition and treatment of complications run alongside any line.
- A pause or stopping anticancer treatment. Sometimes, in poor condition, this is a conscious choice; it is discussed honestly with the doctor and relatives.
How to prepare for the conversation with the doctor
- Bring all scans on discs with reports, especially the first and the latest: comparison with the baseline is critical.
- Write down dates and names of all drugs, with doses and reasons for stopping.
- Note the main symptoms of recent weeks: pain, weight, appetite, temperature.
- Take the pathology and molecular tests, if any.
- Decide in advance what matters most to you: control of disease at any cost, quality of life, ability to work or travel. The choice between options depends on it.
Pseudoprogression, hyperprogression and false alarms
Not every growth on a scan means treatment has failed.
- Pseudoprogression occurs with immunotherapy: a lesion temporarily enlarges because of immune cell infiltration and then shrinks. If the condition is good, the doctor may repeat the scan after 4 to 8 weeks instead of changing regimen at once.
- Hyperprogression is rare: after starting immunotherapy the tumour sharply accelerates. It is an alarming sign and treatment is reviewed quickly.
- Differences in method and scanner. If CT was done in different centres, sizes may differ by millimetres; comparison is better in one place.
- Inflammation, scars and clots sometimes look like new lesions. PET-CT, MRI or biopsy helps. So the radiologist’s report should be discussed with the oncologist, not read as a verdict.
Which tests help choose the next step
- Repeat biopsy. A tumour can change receptor status (for example in breast cancer) or acquire a resistance mutation. This directly affects drug choice.
- NGS panel or liquid biopsy. They show mutations with targeted drugs and MSI, TMB, PD-L1 for immunotherapy.
- PET-CT or MRI for unclear CT findings.
- Blood tests: haemoglobin, liver and kidney function, markers over time: they decide which drugs are acceptable.
- Assessment of condition: weight, appetite, pain, ability to care for yourself. The intensity of the next line depends on it.
How the next line is chosen
The doctor weighs several things: what was already used and how long the effect lasted, molecular findings, toxicity of earlier courses, organ function and your priorities. If the effect lasted long, a similar regimen is sometimes returned to. If not, the drug class is changed.
Good practice: ask the doctor to name two or three options with expected benefit and side effects, not “one regimen”. If a single path is offered without explanation, that is a reason for a second opinion. A document-based consultation takes a few days and does not delay treatment if you agree the timing with your treating doctor.
What to ask your doctor
- Are we sure this is true progression and not pseudoprogression?
- What is the next line and how does it differ in benefit and toxicity?
- Is a repeat biopsy or molecular test needed?
- Are there suitable clinical trials?
If you have been offered a change of regimen or told that options are limited, I can review your documents at a consultation.
Sources
- If Cancer Treatments Stop Working — American Cancer Society
Watch me explain this on video
Short videos on my Instagram (in Russian)
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
